In-stent Restenosis: COMBO Stent May Guarantee a Proper Healing
Keywords:Intra-stent restenosis, Drug-eluting balloon, COMBO-stent, Intravascular ultrasonography.
The risk of ISR appears to be related to several factors which cooperate synergistically; among these factors an important role is played by: the metal struts of the stent and the consequent inflammatory stress on the vascular wall which favors an excessive neointimal proliferation that "attacking" the stent struts, progressively and critically reduce the vessel lumen.
Drug eluting balloon is the gold standard in this setting due to the absence of metallic struts. COMBO stent could be a viable alternative which may properly compare to DEB in the ISR treatment: one of a kind, because it has a dual therapy action, synergistically combining the effect of sirolimus with the presence of CD34+ antibodies on the surface of its struts, capturing circulating endothelial progenitor cells (EPCs), so mobilized EPCs differentiate into functional endothelium and allowing a homogeneous neointimal formation.
Here we are presenting an intriguing case of a ISR treated successfully with COMBO and confirmed by 5-months angiographic and IVUS follow-up.
- Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999;100 (18):1872-1878
- Wijns W, Kolh P, Danchin N et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and te European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous cardiovascular Interventions (EAPCI). Eur. Heart. J. 2010; 31(20): 2501-55. DOI: 10.1093/eurheartj/ehq277.
- 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous cardiovascular Interventions (EAPCI). Eur Heart J, 2014; 35 (37):2541-619. DOI: 10.1093/eurheartj/ehu278.
- Leone AM, Rutella S, Bonanno G et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005 Jun;26(12):1196-204
- Granada JF, Inami S, Aboodi MS et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ.Cardiov. Interv. 2010; 3(3):257-66. DOI: 10.1161/CIRCINTERVENTIONS.109.919936.
- Lee SWL. EGO-COMBO: Combo stent achieved neointimal regression, favorable clinical outcomes. Abstract 367. Presented at: TCT 2014; September 13-17, 2014
- Shewan LG, Coats AJS, Henein M. Requirements for ethical publishing in biomedical journals. International Cardiovascular Forum Journal 2015;2:2 DOI: 10.17987/icfj.v2i1.4
Authors who publish with this journal agree to the following terms:
a. The authors will retain copyright under a Creative Commons Attribution License (CC-BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).